Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations study observed that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://johnk058vtg4.blogoxo.com/profile